Drugs / 3D229
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04941313 | Jul → Nov 2021 | — | 3D Medicines | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2021-03-06 | 3D Medicines (Sichuan) Co., Ltd. | Regulatory 国内首个AXL抑制剂抗体新药临床试验申请获CDE受理 3d-medicines.com ↗
2021年3月6日，思路迪医药（3D Medicines Inc.）宣布，AXL抑制剂（GAS6饵蛋白融合蛋白）3D229注射液的临床试验申请已于日前获国家药品监督管理局药品审评中心（CDE）正式受理，受理号为CXSL2100078，这是该类产品在国内的首个临床申报。 |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2021-07-06 | 3D Medicines (Sichuan) Co., Ltd. | 创新药GAS6/AXL抑制剂 3D229 注射液获准进入MRCT III期临床试验 3d-medicines.com ↗ |
| 2021-03-06 | 3D Medicines (Sichuan) Co., Ltd. | 国内首个AXL抑制剂抗体新药临床试验申请获CDE受理 3d-medicines.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 3D229 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04941313 ↗ |
| Route | Intravenous | “by Intravenous Single Dose Escalation” NCT04941313 ↗ |